Immunophenotyping Is an Independent Factor for Risk Stratification in AML

Cytometry Part B - Clinical Cytometry

Volumn 53, Issue 1, 2003, Pages 11-19

  Repp, Roland ^a,i   Schaekel, U ^b   Helm, G ^a   Thiede, C ^b   Soucek, S ^b   Pascheberg, U ^c   Wandt, H ^d   Aulitzky, W ^e   Bodenstein, H ^f   Sonnen, R ^g   Link, H ^h   Ehninger, G ^b   Gramatzki, M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Klinikum Nuremberg ^*

^d KLINIKUM NÜRNBERG   (Germany)

^e ROBERT BOSCH HOSPITAL   (Germany)

^f KLINIKUM MINDEN   (Germany)

^g DEPARTMENT OF CARDIOLOGY   (Germany)

^h Westpfalz Klinikum GmbH   (Germany)

ⁱ Department of Medicine III   (Germany)

Author keywords

Acute myeloid leukemia AML; Immunophenotyping; Multicenter study; Prognosis; Retrospective study; Risk factors; Statistics

Indexed keywords

ANTIBODY; CD11B ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD64 ANTIGEN; CD9 ANTIGEN; FIBRINOGEN RECEPTOR; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOGENETICS; FEMALE; FOLLOW UP; GERMANY; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICS; ACUTE DISEASE; METHODOLOGY; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; PATHOLOGY; PREDICTION AND FORECASTING; RISK FACTOR; SURVIVAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DAUNORUBICIN; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 10744229044     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.10030     Document Type: Article

References (49)

1. Weir EG, Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol 2001;38:124-138.
2. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-1062.
3. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-4335.
4. Bene MC, Bernier M, Castoldi G, Faure GC, Knapp W, Ludwig WD, Matutes E, Orfao A, van't VM. Impact of immunophenotyping on management of acute leukemias. Haematologica 1999;84:1024-1034.
5. Venditti A, Del PG, Buccisano F, Tamburini A, Cox-Froncillo MC, Aronica G, Bruno A, Del MB, Epiceno AM, Battaglia A, Forte L, Postorino M, Cordero V, Santinelli S, Amadori S. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia 1998;12:1056-1063.
6. Bradstock K, Matthews J, Benson E, Page F, Bishop J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994;84:1220-1225.
7. de Nully BP, Jurlander J, Pedersen-Bjergaard J, Victor MA, Geisler CH. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia. Leuk Res 1997;21:985-995.
8. Chang H, Salma F, Yi Q-L, Patterson BJ, Brien B, Wells R, Schuh A, Brandwein J, Minden MD. Prognostic relevance of immunophenotype in 379 patients with acute myeloid leukemia. Blood 2002;100:256B.
9. Solary E, Casasnovas RO, Campos L, Bene MC, Faure G, Maingon P, Falkenrodt A, Lenormand B, Genetet N. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR-phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Leukemia 1992;6:393-399.
10. Schwarzinger I, Valent P, Koller U, Marosi C, Schneider B, Haas O, Knapp W, Lechner K, Bettelheim P. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 1990;8:423-430.
11. Keyhani A, Huh YO, Jendiroba D, Pagliaro L, Cortez J, Pierce S, Pearlman M, Estey E, Kantarjian H, Freireich EJ. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res 2000;24:153-159.
12. Miyazaki Y, Matsuo T, Kuriyama K, Yoshida S, Tomonaga M, Emi N, Kobayashi T, Miyawaki S, Matsushima T, Shinagawa K, Honda S, Ohno R. The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. JALSG-AML92 study. Blood 2002;100:334A.
13. Campos L, Guyotat D, Archimbaud E, Devaux Y, Treille D, Larese A, Maupas J, Gentilhomme O, Ehrsam A, Fiere D. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989;72:161-166.
14. Lanza F, Rigolin GM, Moretti S, Latorraca A, Castoldi G. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia. Leuk Lymphoma 1994;13 Suppl 1:81-85.
15. Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G, Zittoun R, Casadevall N, Marie JP. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000;96:870-877.
16. Schaich M, Ritter M, Illmer T, Lisske P, Thiede C, Schakel U, Mohr B, Ehninger G, Neubauer A. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol 2001;112:300-307.
17. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192-1200.
18. Gramatzki M, Ludwig WD, Burger R, Moos P, Rohwer P, Grunert C, Sendler A, Kalden JR, Andreesen R, Henschke F, Moldenhauer G. Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol 1998;26:1209-1214.
19. Baum W, Steininger H, Bair HJ, Becker W, Hansen-Hagge TE, Kressel M, Kremmer E, Kalden JR, Gramatzki M. Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL. Br J Haematol 1996;95:327-338.
20. Groeneveld K, te Marvelde JG, van den Beemd MW, Hooijkaas H, van Dongen JJ. Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. Leukemia 1996;10:1383-1389.
21. Mandelli F, Petti MC, Lo CF. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach. Haematologica 1998;83:1015-1023.
22. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322-2333.
23. Rigolin GM, Lanza F, Castoldi G. Photomultiplier voltage setting: possible important source of variability in molecular equivalents of soluble fluorochrome (MESF) calculation? Cytometry 1995;20:362-368.
24. Maynadie M, Gerland L, Aho S, Girodon F, Bernier M, Brunet C, Campos L, Daliphard S, Deneys V, Falkenrodt A, Jacob MC, Kuhlein E, LeCalvez G, Moskovtchenko P, Philip P, Carli PM, Faure GC, Bene MC. Clinical value of the quantitative expression of the three epitopes of CD34 in 300 cases of acute myeloid leukemia. Haematologica 2002;87:795-803.
25. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Loffler H, Riehm H, Schellong G, Ludwig WD. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995;86:3097-3108.
26. Tsao A, Kantarjian HM, Thomas D, Giles FJ, Issa J-P, Cortes JE, Garcia-Manero G, Huh YO, Shen Y, Yang Y, Albitar M, Estey EH. Surface antigen expression in acute leukemias-association with patient and disease characteristics and with outcome. Blood 2002;100:253B.
27. Miwa H, Nakase K, Kita K. Biological characteristics of CD7(+) acute leukemia. Leuk Lymphoma 1996;21:239-244.
28. Schwartz S, Heinecke A, Zimmermann M, Creutzig U, Schoch C, Harbott J, Fonatsch C, Loffler H, Buchner T, Ludwig WD, Thiel E. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma 1999;34:85-94.
29. San Miguel JF, Ojeda E, Gonzalez M, Orfao A, Canizo MC, Sanchez J, Lopez-Borrasca A. Prognostic value of immunological markers in acute myeloblastic leukemia. Leukemia 1989;3:108-111.
30. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA, Tallman MS, Bennett JM, Wiernik PH. Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology Group. Br J Haematol 1998;100:265-272.
31. Griffin JD, Davis R, Nelson DA, Davey FR, Mayer RJ, Schiffer C, McIntyre OR, Bloomfield CD. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood 1986;68:1232-1241.
32. Lee EJ, Yang J, Leavitt RD, Testa JR, Civin CI, Forrest A, Schiffer CA. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. Leukemia 1992;6:1203-1209.
33. Lauria F, Raspadori D, Ventura MA, Rondelli D, Testoni N, Tosi P, Michieli M, Damiani D, Motta MR, Tura S. The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. Stem Cells 1995;13:428-434.
34. Raspadori D, Lauria F, Ventura MA, Rondelli D, Visani G, de VA, Tura S. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res 1997;21:603-607.
35. Sperling C, Buchner T, Creutzig U, Ritter J, Harbott J, Fonatsch C, Sauerland C, Mielcarek M, Maschmeyer G, Loffler H. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. Leuk Lymphoma 1995;17:417-426.
36. Kyoda K, Nakamura S, Hattori N, Takeshima M, Nakamura K, Kaya H, Matano S, Okumura H, Kanno M, Ohtake S, Matsuda T. Lack of prognostic significance of CD34 expression in adult AML when FAB MO and M3 are excluded. Am J Hematol 1998;57:265-266.
37. Reuss-Borst MA, Buhring HJ, Schmidt H, Muller CA. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia 1994;8:258-263.
38. Amirghofran Z, Zakerinia M, Shamseddin A. Significant association between expression of the CD11b surface molecule and favorable outcome for patients with acute myeloblastic leukemia. Int J Hematol 2001;73:502-506.
39. Kanda Y, Hamaki T, Yamamoto R, Chizuka A, Suguro M, Matsuyama T, Takezako N, Miwa A, Kami M, Hirai H, Togawa A. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer 2000;88:2529-2533.
40. Pillay Y, McLellan G, Davison G, Kelly S, Jacobs P. CD7 expression does not predict for poor outcome in acute myeloblastic leukemia. Blood 1995;85:3357-3359.
41. Kornblau SM, Thall P, Huh YO, Estey E, Andreeff M. Analysis of CD7 expression in acute myelogenous leukemia: martingale residual plots combined with 'optimal' cutpoint analysis reveals absence of prognostic significance. Leukemia 1995;9:1735-1741.
42. Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, Wurster-Hill D, Noll W, Elghetany MT, Allen SL. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991;77:2242-2250.
43. Vidriales MB, Orfao A, Gonzalez M, Hernandez JM, Lopez-Berges MC, Garcia MA, Canizo MC, Caballero MD, Macedo A, Landolfi C. Expression of NK and lymphoid-associated antigens in blast cells of acute myeloblastic leukemia. Leukemia 1993;7:2026-2029.
44. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di NR, Pane F, Annunziata M, Schiavone EM, De SM, Guglielmi C, Del VL, Lo CF. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000;18:1295-1300.
45. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 1997;90:1643-1648.
46. Thomas X, Vila L, Campos L, Sabido O, Archimbaud E. Expression of N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome. Leuk Lymphoma 1995;19:295-300.
47. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 2002;87:250-256.
48. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, Sestigiani C, Mariotti C, Birtolo S, Tozzi M, Lauria F. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001;15:1161-1164.
49. Weinkauff R, Estey EH, Starostik P, Hayes K, Huh YO, Hirsch-Ginsberg C, Andreeff M, Keating M, Kantarjian HM, Freireich EJ, Albitar M. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol 1999;111:733-740.